Mechanisms of AVB3 Integrin Mediated Bone Resorption
Mechanisms of AVB3 Integrin Mediated Bone Resorption
批准号:
9013396
负责人:
Steven L Teitelbaum
金额:
$33.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-02-01 至 2020-01-31
关键词:
AddressAttentionBone ResorptionCellsClinical TreatmentClinical TrialsCytoplasmic TailCytoskeletal ModelingCytoskeletonDataDiseaseDrug TargetingEventExerciseFractureFundingGrantHealthInflammatoryIntegrin alphaVbeta3Integrin beta3IntegrinsLigandsMacrophage Colony-Stimulating FactorMediatingMolecular ConformationOsteoclastsOsteolysisOsteolyticOsteoporosisPatientsPlayRestRiskRoleSRC geneSignal TransductionSignaling MoleculeTalinTherapeuticbisphosphonatebonec-fms Proto-Oncogenesin vivonew therapeutic targetosteoporosis with pathological fracturereceptorskeletalsuccess
中文摘要
描述(由申请人提供):根据我们和其他人的观察,αvβ3整合素是目前治疗骨质疏松症和炎症性骨溶解等疾病的抗吸收靶点。从一开始,这项资助的目的就是通过表征整合素的相关分子和它们传递的骨降解信号来扩大治疗靶向整合素的潜力。除了那些抑制αvβ3的药物外,针对OCs中整合素效应的信号分子(如c-Src和Syk)的药物正在进行溶骨性疾病的临床试验,这一事实强调了这项工作的成功。在过去的筹资期间,我们已经实现了我们的具体目标。虽然我们继续努力确定αvβ3调节OC的机制,特别是在组织其细胞骨架的衍生信号的背景下,我们目前的注意力转向整合素本身。我们解决的机制,其中整合素假设一个激活的构象,允许它识别配体和传递其骨吸收信号。我们和其他人的研究结果表明,M-CSF在这方面起着核心作用。我们已经确定αvβ3和M-CSF协同组织OC细胞骨架。然而,我们的数据表明,M-CSF发挥其细胞骨架效应的主要手段是促使其受体c-Fms将细胞内信号传递到β3整合素亚基的细胞质结构域。这些信号依次将整合素从其默认的静止状态转运到其激活的构象,从而允许配体识别和细胞骨架组织事件。我们的研究结果还表明,talin通过与β3整合素细胞质域的特定残基相互作用,激活OC αvβ3及其衍生的信号。因此,我们假设:1)M-CSF与其受体c-Fms结合,传递激活OCs中αvβ3整合素的胞内信号;2) talin及其在β3胞质域的识别序列介导m - csf诱导的OC细胞骨架组织和功能;3)在体内抑制αvβ3的活化,减少病理性骨吸收。因此,我们的具体目标是确定1)M-CSF与其受体c-Fms相互作用的机制,通过传递激活OCs中αvβ3整合素的细胞内信号;2) β3整合素胞质域talin及其识别序列在介导m - csf诱导的OC细胞骨架组织和功能中的作用;3)体内抑制αvβ3活化对病理性骨吸收的影响。
英文摘要
DESCRIPTION (provided by applicant): Prompted by our observations and those of others, the αvβ3 integrin is a current therapeutic anti-resorptive target for diseases such as osteoporosis and inflammatory osteolysis. The purpose of this grant, from its inception, has been to expand the potential of therapeutically targeting the integrin by characterizing its associated molecules and the bone-degrading signals they transmit. The success of this exercise is underscored by the fact that in addition to those inhibiting αvβ3, drugs targeting signaling molecules, such as c-Src and Syk, which are effectors of the integrin, in OCs, are in clinical trial for osteolytic diseases. We have, in the past funding period, fulfilled our specific aims. While our efforts continue to define the mechanisms by which αvβ3 regulates the OC, particularly in the context of derivative signals which organize its cytoskeleton, our current attention turns to the integrin, itself. We address the mechanisms by which the integrin assumes an activated conformation which permits it to recognize ligand and transmit its bone-resorptive signals. Our findings and those of others, indicate M-CSF plays a central role in this regard. We have established that αvβ3 and M-CSF collaborate in organizing the OC cytoskeleton. Our data indicate, however, that the principal means by which M-CSF exerts its cytoskeletal effect is to prompt its receptor c-Fms to transmit intracellular signals to the cytoplasmic domain of the β3 integrin subunit. These signals, in turn, transit the integrin from its default, resting state, to its activated conformation, permitting ligand recognition and cytoskeleton-organizing events. Our findings also suggest that talin activates OC αvβ3 and the signals derived thereof, by interacting with specific residues in the β3 integrin cytoplasmic domain. We hypothesize, therefore that 1) M-CSF, liganding its receptor, c-Fms, transmits intracellular signals which activate the αvβ3 integrin in OCs; 2) talin and its recognition sequences in the β3 cyoplasmic domain mediate M-CSF-induced OC cytoskeletal organization and function and 3) inhibiting αvβ3 activation, in vivo, diminishes pathological bone resorption. Our specific aims are therefore to determine 1) the mechanism by which M-CSF, interacting with its receptor c-Fms, transmits intracellular signals which activate the αvβ3 integrin in OCs; 2) the role of talin and its recognition sequences in the β3 integrin cytoplasmic domain in mediating M-CSF-induced OC cytoskeletal organization and function and 3) the impact of inhibiting αvβ3 activation, in vivo, on pathological bone resorption.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hepatic steatosis promotes liver metastasis
-
批准号:10365691
-
项目类别:
-
资助金额:$45.72万
-
财政年份:2022
-
负责人:Steven L Teitelbaum
-
依托单位:
Hepatic steatosis promotes liver metastasis
-
批准号:10545090
-
项目类别:
-
资助金额:$47.08万
-
财政年份:2022
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:9978044
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:10163838
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:9526487
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:9754825
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Rankl Mediated Osteoclast Activation
-
批准号:7812306
-
项目类别:
-
资助金额:$43.87万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
MECHANISMS OF POLARIZED SECRETION BY BONE CELLS
-
批准号:7858352
-
项目类别:
-
资助金额:$33.86万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
CDC 42 BIM AND THE OSTEOCLAST
-
批准号:7729102
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
MECHANISMS OF POLARIZED SECRETION BY BONE CELLS
-
批准号:7633796
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Polarized Secretion by Bone Cells
-
批准号:8274354
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Polarized Secretion by Bone Cells
-
批准号:8493782
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Polarized Secretion by Bone Cells
-
批准号:8076266
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
CDC 42 BIM AND THE OSTEOCLAST
-
批准号:7934686
-
项目类别:
-
资助金额:$37.82万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6508327
-
项目类别:
-
资助金额:$34.91万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6933118
-
项目类别:
-
资助金额:$34.23万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:7118802
-
项目类别:
-
资助金额:$33.43万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6630326
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6792769
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
MECHANISMS OF AVB3 INTEGRIN MEDIATED BONE RESORPTION
-
批准号:6349974
-
项目类别:
-
资助金额:$30.17万
-
财政年份:2000
-
负责人:Steven L Teitelbaum
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位: